Navigation Links
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
Date:12/18/2007

patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia.

Safe Harbor Statement

This press release includes forward-looking statements regarding the potential timing of the completion and announcement of results of the AZ-104 Phase 2a clinical trial, potential benefits of AZ-104, future development of the Company's product candidates and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Final results from,a 24-week study presented today at ... olanzapine long-acting injection (LAI),therapeutic doses showed a maintenance ... review of pooled safety data from all olanzapine ... Olanzapine LAI is an investigational formulation that ...
... 2 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the signature of ... de Lausanne (EPFL), aimed at the identification ... with pathways controlling cell fate,specification. The project, ...
Cached Medicine Technology:Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 2Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 3Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 4Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 5Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 6Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 7Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 8Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 9Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment 2
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... ... refusing travellers with symptoms similar to flu to board planes, travel insurers are treating swine ... ... AA Travel Insurance are now enquiries from travellers concerned about whether they are covered if ...
... who struggle with CPAP treatment for obstructive sleep apnea ... the upper airway, because it holds the same quality-of-life ... in new research published in the August 2009 edition ... positive airway pressure (CPAP) therapy is a highly effective ...
... Speaker Nancy Pelosi issued the following statement tonight on the vote ... Affordable Health Choices Act, the third House committee to pass the ... Education and Labor Committee approved the bill earlier this month: ... have tried as a nation to make quality, affordable health insurance ...
... for people living with AIDS and increases with increasing ... 31 in the Journal of the National Cancer ... is known to be higher among people with AIDS, ... is unclear. Anil K. Chaturvedi, Ph.D., of the ...
... , NEW YORK, July 31 BBV Vietnam ... "Company") announced today that it has signed a non-binding letter of ... Pursuant to the provisions of the Company,s Articles of Incorporation, the ... combination. If the Company is unable to complete the business combination ...
... more health and social issues years later , FRIDAY, July ... neuroblastoma face long-term health and social problems, according to a ... who had been diagnosed with neuroblastoma -- a cancer that ... comparing it with data on 3,899 siblings of children with ...
Cached Medicine News:Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 2Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 4Health News:AIDS patients face higher risk of HPV-related cancers as immunosuppression grows 2Health News:BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc. 2
... Launched in 1996, VISIPAQUE is the only isosmolar ... an osmolality equal to that of blood, VISIPAQUE ... is also the only contrast medium formulated with ... blood. In 1997, VISIPAQUE received FDA approval for ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Castroviejo caliper...
Medicine Products: